Cue Biopharma, Inc. Operating Cash Flow
Cue Biopharma, Inc. (CUE) reported Operating Cash Flow of -$39.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Cue Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$29.00M.
- Cue Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$10.94M.
- Cue Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.08M.
- Cue Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.02M.
- Cue Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$21.69M.
- Cue Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$36.33M.
- Cue Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$39.96M.
- Cue Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$41.81M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$29.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$39.95M 10-Q · filed 2026-08-14 | -$41.02M derived: sum of 3 quarters · filed 2026-08-14 | -$50.05M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$10.94M 10-Q · filed 2026-05-14 | -$12.02M derived: sum of 2 quarters · filed 2026-05-14 | -$21.04M derived: sum of 3 quarters · filed 2026-05-14 | -$24.46M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$10.10M derived: sum of 2 quarters · filed 2026-03-16 | -$13.52M derived: sum of 3 quarters · filed 2026-08-14 | -$21.69M 10-K · filed 2026-03-16 | |
| 2025-09-30 | -$9.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$12.44M derived: sum of 2 quarters · filed 2026-08-14 | -$20.61M 10-Q · filed 2025-11-12 | -$29.64M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$11.59M 10-Q · filed 2026-08-14 | -$20.61M derived: sum of 3 quarters · filed 2026-08-14 | -$28.14M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$8.17M 10-Q · filed 2026-05-14 | -$17.20M derived: sum of 2 quarters · filed 2026-05-14 | -$24.73M derived: sum of 3 quarters · filed 2026-05-14 | -$34.72M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$9.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$16.55M derived: sum of 2 quarters · filed 2026-03-16 | -$26.55M derived: sum of 3 quarters · filed 2026-03-16 | -$36.33M 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$7.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$17.52M derived: sum of 2 quarters · filed 2025-11-12 | -$27.30M 10-Q · filed 2025-11-12 | -$38.26M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$9.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$19.77M 10-Q · filed 2025-08-12 | -$30.73M derived: sum of 3 quarters · filed 2025-08-12 | -$38.53M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$9.78M 10-Q · filed 2025-05-12 | -$20.74M derived: sum of 2 quarters · filed 2025-05-12 | -$28.54M derived: sum of 3 quarters · filed 2025-05-12 | -$38.91M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$10.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$18.76M derived: sum of 2 quarters · filed 2025-03-31 | -$29.13M derived: sum of 3 quarters · filed 2025-03-31 | -$39.96M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$7.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$18.17M derived: sum of 2 quarters · filed 2024-11-14 | -$29.00M 10-Q · filed 2024-11-14 | -$39.52M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$10.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$21.20M 10-Q · filed 2024-08-14 | -$31.72M derived: sum of 3 quarters · filed 2024-08-14 | -$38.59M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$10.83M 10-Q · filed 2024-05-09 | -$21.35M derived: sum of 2 quarters · filed 2024-05-09 | -$28.22M derived: sum of 3 quarters · filed 2024-05-09 | -$41.07M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$10.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$17.39M derived: sum of 2 quarters · filed 2024-03-28 | -$30.23M derived: sum of 3 quarters · filed 2024-03-28 | -$41.81M 10-K · filed 2024-03-28 | -$41.81M 10-K · filed 2023-03-21 |
| 2022-09-30 | -$6.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$19.72M derived: sum of 2 quarters · filed 2023-11-03 | -$31.29M 10-Q · filed 2023-11-03 | -$41.94M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | -$12.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$24.42M 10-Q · filed 2023-08-08 | -$35.07M derived: sum of 3 quarters · filed 2023-08-08 | -$41.69M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$11.57M 10-Q · filed 2023-05-09 | -$22.22M derived: sum of 2 quarters · filed 2023-05-09 | -$28.85M derived: sum of 3 quarters · filed 2023-05-09 | -$38.62M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$10.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | -$17.27M derived: sum of 2 quarters · filed 2023-03-21 | -$27.04M derived: sum of 3 quarters · filed 2023-03-21 | -$38.84M 10-K · filed 2023-03-21 | |
| 2021-09-30 | -$6.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$16.40M derived: sum of 2 quarters · filed 2022-11-14 | -$28.19M 10-Q · filed 2022-11-14 | -$35.19M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$9.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$21.57M 10-Q · filed 2022-08-04 | -$28.56M derived: sum of 3 quarters · filed 2022-08-04 | -$36.25M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$11.79M 10-Q · filed 2022-05-10 | -$18.79M derived: sum of 2 quarters · filed 2022-05-10 | -$26.48M derived: sum of 3 quarters · filed 2022-05-10 | -$33.35M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$14.69M derived: sum of 2 quarters · filed 2022-03-16 | -$21.55M derived: sum of 3 quarters · filed 2022-03-16 | -$32.49M 10-K · filed 2022-03-16 | |
| 2020-09-30 | -$7.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$14.55M derived: sum of 2 quarters · filed 2021-11-09 | -$25.50M 10-Q · filed 2021-11-09 | -$31.93M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | -$6.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$17.81M 10-Q · filed 2021-08-09 | -$24.25M derived: sum of 3 quarters · filed 2021-08-09 | -$33.45M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | -$10.94M 10-Q · filed 2021-05-10 | -$17.38M derived: sum of 2 quarters · filed 2021-05-10 | -$26.59M derived: sum of 3 quarters · filed 2021-05-10 | -$33.27M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$6.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$15.65M derived: sum of 2 quarters · filed 2021-03-09 | -$22.32M derived: sum of 3 quarters · filed 2021-03-09 | -$30.80M 10-K · filed 2021-03-09 | |
| 2019-09-30 | -$9.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$15.88M derived: sum of 2 quarters · filed 2020-11-09 | -$24.36M 10-Q · filed 2020-11-09 | -$28.26M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | -$6.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$15.15M 10-Q · filed 2020-08-07 | -$19.05M derived: sum of 3 quarters · filed 2020-08-07 | -$25.35M derived: sum of 4 quarters · filed 2020-08-07 | |
| 2019-03-31 | -$8.47M 10-Q · filed 2020-05-07 | -$12.37M derived: sum of 2 quarters · filed 2020-05-07 | -$18.67M derived: sum of 3 quarters · filed 2020-05-07 | -$25.13M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | -$3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$10.20M derived: sum of 2 quarters · filed 2020-03-12 | -$16.65M derived: sum of 3 quarters · filed 2020-03-12 | -$26.41M 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$6.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$12.75M derived: sum of 2 quarters · filed 2019-11-07 | -$22.51M 10-Q · filed 2019-11-07 | -$24.36M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | -$6.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$16.21M 10-Q · filed 2019-08-08 | -$18.06M derived: sum of 3 quarters · filed 2019-08-08 | -$21.74M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | -$9.76M 10-Q · filed 2019-05-08 | -$11.60M derived: sum of 2 quarters · filed 2019-05-08 | -$15.28M derived: sum of 3 quarters · filed 2019-05-08 | ||
| 2017-12-31 | -$1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$5.52M derived: sum of 2 quarters · filed 2019-03-14 | -$12.14M 10-K · filed 2019-03-14 | ||
| 2017-09-30 | -$3.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$10.30M 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | -$6.62M 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |